Genpact and analyst firm HFS Research have published a new global study, ‘The $18 Trillion Opportunity: How Four Enterprise ...

In the first piece of news from the BIO conference that gets underway in San Diego today, Insilico Medicine has teamed up ...

Paulo Fontoura, currently chief medical officer of Xaira Therapeutics, will replace Houman Ashrafian as Sanofi's R&D head on 1st September. The R&D baton at Sanofi will soon be handed over, as the ...

Details are starting to emerge of last week's cyberattack on Novo Nordisk, which now appears to have been a $25 million ...

Biogen has dipped its toe into the M&A waters once again, agreeing to buy San Diego-based RayThera for up to $1 billion in ...

The first generic alternative to Roche's oral drug for influenza, Xofluza, has been approved by the FDA and should be ...

Sanofi's neurology pipeline has had a hole blown in it after a phase 3 trial of riliprubart (SAR445088) in rare disease ...

The FDA refused to accept uniQure's filing for AMT-130 last November, and earlier this year the Dutch biotech said it had ...

Men with a particular form of prostate cancer now have a targeted treatment for the first time, thanks to FDA approval of a ...

The late-stage MonumenTAL-3 trial of Talvey (talquetamab), given in combination with J&J and Genmab's anti-CD38 antibody ...

As such, Google AI Overviews represent a major shift in search for the pharma industry, moving from traditional link-based ...

Capvaxive, which covers 21 strains of Streptococcus pneumoniae, has been approved since 2024 for the prevention of invasive ...